Replies to post #724377 on NorthWest Biotherapeutics Inc (NWBO)

[Horseb4CarT]

Thanks I will look at the reference and let you know what I think.

Regarding HIV, I am aware of the postings, and I believe in a Dr Bosch presentation, that imply that the same basic approach that applies to cancer antigens should apply to other (non cancer) entities that should not be present for normal cells.

I haven’t spent the effort to perform that due diligence yet however I am assuming probable applicability unless shown differently, and the cancer opportunities are so humongous that in the short term they should propel the company and the stock, and help a great many people.

Generalization beyond cancer is ginormous and mind boggling, and if successful could be the biggest medical treatment platform technology of all time!!!

[Horseb4CarT]

Dstock,

I skimmed the linked document and see that this other DC platform technology is attempting to address cancers and viruses, thus supporting the development of dcvax being able to address the same.

Imo dcvax should be the more effective platform than those that target a more limited subset of enemy antigens, since dcvax DCs present as many antigens as possible for the DCs to pick up from the lysate.

That’s why dcvax L has been the most successful against gbm, because the informed immune response is against hundreds of antigens and gbm is very diverse to begin with and highly mutational. In fact dcvax works better against “hot” tumors than less “hot” tumors.

In summary, yes there is potential for dcvax cancers, viruses, and possibly more!!!